Reported about 1 month ago
Reckitt Benckiser Group reported a smaller decline in third-quarter sales than expected, thanks to an increase in consumer purchases of health products like Nurofen and Strepsils. Shares rose over 3% in response to improving sales volumes after a challenging year marked by an internal investigation and litigation issues in its nutrition business. Despite a 0.5% drop in like-for-like net sales, the company's performance was better than forecasts, and it continues to focus on healthcare and hygiene while considering future strategies.
Source: YAHOO